Pharmagen Laboratories Remains Industry Leader on Patient Safety

       Pharmagen Laboratories Remains Industry Leader on Patient Safety

PR Newswire

SILVER SPRING, Md., April 10, 2013

SILVER SPRING, Md., April 10, 2013 /PRNewswire/ --Pharmagen, Inc. (OTCBB:
PHRX) (the "Company" or "Pharmagen") is excited to announce that it has
entered into an agreement to use proprietary ScanRDI technology from
BioMerieux. Pharmagen Laboratories is only one of five sterile compounding
companies in the United States to use ScanRDI, a cutting edge technology that
reduces the method time for product sterility testing from 14 days to less
than 3 hours. Utilizing solid phase cytometry in conjunction with fluorescent
viability staining, ScanRDI allows for product sterility results in a matter
of minutes. This is the only technology in the world that can detect
contamination down to one viable microorganism without the need for growth or
enrichment. While most compounding companies randomly skip-lot test, Pharmagen
Laboratories tests every lot, every time. With this new, unparalleled
turnaround time, Pharmagen can now produce new compounds in a matter of hours
– giving the company an enormous competitive advantage in responding to an
ever-changing market place.

"Patient safety in compounding has become a hot topic after New England
Compounding Center's meningitis outbreak and there isn't another company out
there that takes it as seriously as we do. Pharmagen has passed recent FDA and
State Board of Pharmacy inspections, in addition to hiring an industry leading
consulting firm, Kymanox, for an independent review. Taking lessons from the
pharmaceutical manufacturing space, we're instituting cutting edge Standard
Operating Procedures, and as many USP and cGMP guidelines as we can in a
compounding environment. We see competitors testing a small percentage of what
leaves their facilities. Products from typical compounding facilities are
shipped prior to having test results in hand, resulting in recalls on an
almost daily basis. Pharmagen tests absolutely everything we produce and
nothing leaves our facility until we know it's safe," said Mackie A. Barch,
CEO of Pharmagen.

"Additionally, the demands of the health provider market are extremely
dynamic. Being able to save two weeks give us a real advantage because two
weeks is a lifetime in this business – both for us and the patients we
ultimately serve," continued Barch.

About Pharmagen

Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating
divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and
Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the
nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen
is meeting the demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions. Nationally focused,
Pharmagen is a dynamic distributor of specialty drugs, compounding and admix
pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the
healthcare provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are hard-to-find due to
drug manufacturers' production shortages.

About Kymanox

Kymanox, with headquarters now in RTP, NC, is a premier technical products and
technical project management company. We have expertise in providing
engineering, scientific, regulatory, and process development support to
companies involved in Biopharmaceutical, Medical Device, and Nanotechnology
development. Kymanox has a proven track record in solving complex scale-up,
technology transfer, and manufacturing problems – as well as receiving
positive feedback from the FDA on executing complex approval pathways for next
generation drugs. With our focus on commercialization, Kymanox helps bring
new products to patients in need.

Contact: 888-264-4597,

Safe Harbor Statement
Information in this document constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
The words "forecast", "anticipate", "estimate", "project", "intend", "expect",
"should", "believe", and similar expressions are intended to identify
forward-looking statements. These forward-looking statements involve, and are
subject to known and unknown risks, uncertainties and other factors which
could cause Pharmagen actual results, performance (financial or operating) or
achievements to differ from the future results, performance (financial or
operating) or achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more fully
discussed in Pharmagen' filings with the U.S. Securities and Exchange
Commission. All forward-looking statements attributable to Pharmagen herein
are expressly qualified in their entirety by the above-mentioned cautionary
statement. Pharmagen disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by law.

SOURCE Pharmagen, Inc.

Press spacebar to pause and continue. Press esc to stop.